In this article we review recent advances made in the pathophysiology, diagnosis, and
treatment of inhalation injury. Historically, the diagnosis of inhalation injury has relied on …

Nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale and
warrants urgent investigation of its therapeutic potential, for COVID-19-induced acute …

Biologic products are large molecules such as proteins, peptides, nucleic acids, etc., which
have already produced many new drugs for clinical use in the last decades. Due to the …

Acute respiratory distress syndrome (ARDS) presents a complex pathophysiology
characterized by pulmonary activated coagulation and reduced fibrinolysis. Despite …

Introduction Smoke inhalation injury (II) is an independent risk factor for mortality in burns
and its management is inherently complex. We aim to make recommendations for best …

Aerosol therapy is a key modality for drug delivery to the lungs of respiratory disease
patients. Aerosol therapy improves therapeutic effects by directly targeting diseased lung …

Pneumonia, inhalation trauma and acute respiratory distress syndrome (ARDS), typical
causes of lung injury in critically ill patients, are all three characterized by dysregulated …

Smoke-inhalation-induced acute lung injury (SI-ALI) is a leading cause of morbidity and
mortality in victims of fire tragedies. SI-ALI contributes to an estimated 30% of burn-caused …

Introduction Systematic reviews collate trial data to provide evidence to support clinical
decision-making. For effective synthesis, there must be consistency in outcome reporting …

The defining features of acute respiratory distress syndrome (ARDS) are an excessive
inflammatory respiratory response associated with high morbidity and mortality. Treatment …